Cancer Genomics & Proteomics

Scope & Guideline

Connecting researchers and clinicians in the fight against cancer.

Introduction

Welcome to the Cancer Genomics & Proteomics information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Cancer Genomics & Proteomics, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1109-6535
PublisherINT INST ANTICANCER RESEARCH
Support Open AccessNo
CountryGreece
TypeJournal
Convergefrom 2004 to 2024
AbbreviationCANCER GENOM PROTEOM / Cancer Genomics Proteomics
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE

Aims and Scopes

The journal 'Cancer Genomics & Proteomics' is dedicated to advancing the understanding of cancer through the integration of genomic and proteomic data. It aims to disseminate research that explores the molecular mechanisms underlying cancer biology, therapeutic responses, and the development of novel biomarkers for diagnosis and treatment.
  1. Genomic Characterization of Cancers:
    The journal publishes studies that focus on the genetic alterations in various cancers, including large-scale genomic analyses that identify mutations, copy number variations, and other genomic features that drive cancer progression.
  2. Proteomic Profiling and Biomarker Discovery:
    Research highlighting the role of proteomics in understanding cancer biology and identifying potential biomarkers for diagnosis and prognosis is a core focus area, with studies employing advanced proteomic techniques.
  3. Therapeutic Strategies and Drug Resistance:
    Papers examining novel therapeutic approaches, mechanisms of drug resistance, and the development of targeted therapies based on genomic and proteomic insights are emphasized.
  4. Cancer Microenvironment and Immunology:
    The journal explores the interactions between cancer cells and their microenvironment, including studies on immune responses, tumor-stroma interactions, and the implications for therapy.
  5. Translational Research and Clinical Implications:
    Research that bridges laboratory findings with clinical applications, including studies that assess the clinical utility of genomic and proteomic findings in patient management, is a significant aspect of the journal.
The journal 'Cancer Genomics & Proteomics' has identified several trending and emerging themes that reflect the evolving landscape of cancer research. These themes highlight areas of increasing interest and innovation within the field.
  1. Novel Therapeutic Targets and Strategies:
    Recent publications are increasingly focusing on identifying new therapeutic targets based on genomic and proteomic data, particularly in the context of personalized medicine and targeted therapies.
  2. Role of Non-coding RNAs in Cancer:
    There is a rising trend in research exploring the role of non-coding RNAs, including circular RNAs and long non-coding RNAs, in cancer biology, which are being recognized for their potential as biomarkers and therapeutic targets.
  3. Cancer Metabolism and Microenvironment:
    Studies examining the metabolic adaptations of cancer cells and the influence of the tumor microenvironment on cancer progression and therapy response are gaining prominence, reflecting a broader interest in the metabolic aspects of cancer.
  4. Immunotherapy and Immune Profiling:
    Emerging research focusing on the immune landscape of tumors, including the role of immune checkpoints and the tumor microenvironment in modulating immune responses, is increasingly prevalent.
  5. Integration of Multi-Omics Approaches:
    There is a growing interest in studies that integrate genomic, proteomic, and metabolomic data to provide a comprehensive understanding of cancer biology and to identify novel biomarkers and therapeutic strategies.

Declining or Waning

While 'Cancer Genomics & Proteomics' has a robust focus on various aspects of cancer research, certain themes have shown a decline in prominence over recent years. This may reflect shifts in research priorities or the emergence of new areas of interest.
  1. Basic Science Studies Without Clinical Relevance:
    There has been a noticeable decrease in publications that focus solely on basic cancer biology without clear translational or clinical implications, as the journal increasingly emphasizes studies that directly inform patient care.
  2. Single-Modality Studies:
    Research focusing exclusively on either genomic or proteomic analysis, without integration, appears to be declining. The trend is moving towards more comprehensive studies that combine both modalities for a more holistic understanding of cancer.
  3. Older Therapeutic Approaches:
    Papers centered on traditional therapeutic approaches, such as chemotherapy without genomic context, are less frequent. The journal seems to be favoring innovative and targeted therapeutic strategies backed by molecular data.

Similar Journals

MOLECULAR & CELLULAR PROTEOMICS

Innovating the future of molecular and cellular studies.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

Cancer Biomarkers

Exploring Novel Frontiers in Cancer Research.
Publisher: IOS PRESSISSN: 1574-0153Frequency: 12 issues/year

Cancer Biomarkers is a leading journal in the field of cancer research, aimed at the exploration and identification of novel biomarkers for cancer detection, prognosis, and therapy. Published by IOS PRESS in the Netherlands, this journal serves as a pivotal resource for those engaged in oncology, genetics, and molecular biology, facilitating access to cutting-edge research and advancements within these disciplines. In its ongoing mission since 2005, the journal has become an essential reference point, currently occupying a Q3 category in Cancer Research, Genetics, and Oncology, and a Q2 category in miscellaneous Medicine fields. With its commitment to high-quality peer-reviewed articles, Cancer Biomarkers satisfies the intellectual appetite of researchers, clinicians, and students alike, contributing significantly to the ever-evolving landscape of cancer biomarker discovery and application. Though currently not available as Open Access, the journal maintains a robust presence in academic circles, underscored by respectable Scopus rankings across relevant categories.

Biomarker Insights

Transforming health insights through groundbreaking research.
Publisher: SAGE PUBLICATIONS LTDISSN: 1177-2719Frequency: 1 issue/year

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

MOLECULAR CARCINOGENESIS

Decoding the Pathways of Cancer Development
Publisher: WILEYISSN: 0899-1987Frequency: 12 issues/year

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

Proteome Science

Connecting Researchers in the Quest for Protein Knowledge
Publisher: BMCISSN: Frequency: 1 issue/year

Proteome Science is an esteemed academic journal specializing in the field of proteomics, providing a platform for advanced research and discussions surrounding the structure, function, and dynamics of proteins in biological systems. Published by BMC, a reputable publisher recognized for its commitment to open-access publishing, Proteome Science has been disseminating pivotal research findings since its inception in 2003. Targeted towards researchers, professionals, and students in biochemistry and molecular biology, the journal aims to foster collaboration and innovation within the scientific community. While it currently holds a Q3 quartile ranking in both Biochemistry and Molecular Biology categories, its impactful contributions to the field are reflected in its accessibility, as evidenced by its open access policy. By embracing collaborative research methodologies and providing a platform for novel findings, Proteome Science plays a crucial role in advancing the understanding of proteomic analyses, catering to a global audience that values groundbreaking scientific discovery.

JOURNAL OF GENE MEDICINE

Bridging Laboratory Discoveries with Clinical Applications
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Annual Review of Cancer Biology

Unraveling Innovations in Oncology
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

Physiology and Pharmacology

Empowering researchers through open access knowledge.
Publisher: IRANIAN SOC PHYSIOLOGY & PHARMACOLOGYISSN: 2476-5236Frequency: 4 issues/year

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

Translational Cancer Research

Fostering collaboration for a cancer-free future.
Publisher: AME PUBLISHING COMPANYISSN: 2218-676XFrequency: 12 issues/year

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

PATHOLOGY RESEARCH AND PRACTICE

Innovating Diagnostics and Forensic Insights
Publisher: ELSEVIER GMBHISSN: 0344-0338Frequency: 12 issues/year

PATHOLOGY RESEARCH AND PRACTICE is a premier journal in the field of pathology and forensic medicine, published by Elsevier GmbH in Germany. With a rich publication history since 1978 and an impressive convergence period extending to 2024, this journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of pathological processes. It holds notable rankings, including Q3 in Cell Biology and Q2 in Pathology and Forensic Medicine for 2023, reflecting its significance in the academic community. The journal aims to publish innovative research findings, reviews, and case studies, facilitating a deeper understanding of disease mechanisms and improving diagnostic practices. Authors and readers alike benefit from its reputable platform, noted for its challenging and rigorous peer-review process. By fostering a collaborative environment and providing open access options, PATHOLOGY RESEARCH AND PRACTICE continues to contribute meaningfully to the discourse within its respective fields, thereby appealing to a diverse audience of researchers, professionals, and students.